|Bid||25.08 x 800|
|Ask||25.02 x 800|
|Day's Range||24.96 - 25.30|
|52 Week Range||15.35 - 25.30|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 27, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.44|
Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy. The data are being presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021, and in an investor webcast presentation hosted by the company.
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 10:30 a.m. ET (3:30 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.